



15005088



Received SEC

FEB 02 2015

001-36828

William Slattery, CFA  
Vice President  
Listing Qualifications

Washington, DC 20549

By Electronic Mail

February 2, 2015

*CENTAS*

Mr. Jeffrey Thomas  
Chief, IT Services  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on January 30, 2015, The Nasdaq Stock Market (the "Exchange") received from Nexvet Biopharma public limited company (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

air  
nta P  
nc  
Ordinary Shares, \$0.125 nominal value

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Division of Corporation Finance  
U.S. Securities and Exchange Commission

Sincerely,

W.S.

*William Slattery*

This is to certify that on January 30, 2015, The Nasdaq Stock Market (the "Exchange") received from Nexvet Biopharma public limited company (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

air  
nta P  
nc  
Ordinary Shares, \$0.125 nominal value